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Background: The benefit of adjuvant chemotherapy in postmenopausal patients with estrogen receptor (ER)-
positive lymph node-negative breast cancer is being reassessed.
Patients and methods: After stratification by ER status, 1669 postmenopausal patients with operable lymph node-
negative breast cancer were randomly assigned to three 28-day courses of ‘classical’ CMF (cyclophosphamide,
methotrexate, 5-fluorouracil) chemotherapy followed by tamoxifen for 57 months (CMF/tamoxifen) or to tamoxifen
alone for 5 years.
Results: ERs were positive in 81% of tumors. At a median follow-up of 13.1 years, patients with ER-positive breast
cancers did not benefit from CMF [13-year disease-free survival (DFS) 64% CMF/tamoxifen, 66% tamoxifen;
P = 0.99], whereas CMF substantially improved the prognosis of patients with ER-negative breast cancer (13-year
DFS 73% versus 57%, P = 0.001). Similarly, breast cancer-free interval (BCFI) was identical in the ER-positive cohort
but significantly improved by chemotherapy in the ER-negative cohort (13-year BCFI 80% versus 63%, P = 0.001).
CMF had no influence on second nonbreast malignancies or deaths from other causes.
Conclusion: CMF is not beneficial in postmenopausal patients with node-negative ER-positive breast cancer but is
highly effective within the ER-negative cohort. In the future, other markers of chemotherapy response may define
a subset of patients with ER-positive tumors who may benefit from adjuvant chemotherapy.
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introduction
In recent years, the use of adjuvant chemotherapy in women
with node-negative postmenopausal breast cancer has been
increasingly questioned, and the identification of patients
who might be spared chemotherapy is one of the current
priorities of clinical research [1]. While RNA expression-
based multigene markers have the potential to identify
patients who benefit from chemotherapy [2], they are not
universally available because of substantial cost to consumers
and because of logistic issues in many countries; in addition,
while retrospective analyses of the performance of such tests
are promising, they have not yet been proven useful in
randomized prospective trials. In contrast, the determination
of estrogen receptors (ERs) by immunohistochemistry is very
widely available worldwide and was found to predict the
efficacy of chemotherapy [3–5]. The International Breast
Cancer Study Group (IBCSG) Trial IX, a prospective
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chemoendocrine therapy in women with postmenopausal
node-negative breast cancer, found that the substantial
benefit of chemotherapy with oral cyclophosphamide,
methotrexate and fluorouracil (CMF) was limited to patients
with low or absent ER expression; patients with ER-positive
breast cancer did not benefit from chemotherapy at a median
follow-up of 5.9 years [6]; similar findings were reported by
other collaborative groups [7]. The present report updates
IBCSG Trial IX at 13.1 years median follow-up, comparing
adjuvant endocrine with chemoendocrine therapy according
to ER expression.
patients and methods
The design of IBCSG Trial IX and the patient population have been
described in a prior report [6]. In 1988, tamoxifen was used in the adjuvant
therapy of postmenopausal women irrespective of the ER status of the
breast cancer, although some evidence pointed to a superior efficacy in
patients with ER-positive tumors. Randomization was stratified according
to ER status, and the intention to perform separate analysis according to ER
status was specified in the original protocol. This analysis was limited to
the 1646 eligible patients with known ER status of the 1715 randomized
(Table 1).
All patients had histologically proven unilateral breast cancer of stage T1a
to T3, pN0, M0, with either ER-positive or ER-negative primary tumors.
Surgery of the primary tumor was either a total mastectomy or a breast-
conserving procedure (quadrantectomy or lumpectomy); axillary lymph
node dissection was mandatory. Radiation therapy was recommended for
completing breast conservation and was postponed until the end of
chemotherapy. Postmenopausal status was defined as having one of the
following sets of characteristics: (i) older than 52 years with at least 1 year of
amenorrhea; (ii) 52 years old or younger with at least 3 years of
amenorrhea; (iii) 56 years old or older with hysterectomy but no bilateral
oophorectomy; or (iv) biochemical evidence of cessation of ovarian
function (for doubtful patients). Staging before randomization included
chest X-ray, contralateral mammogram, bone scintigram (if clinically
indicated), and hematological, liver, and renal function tests. Clinical,
hematological, and biochemical assessments were required every 3 months
for the first year, every 6 months for the second year, and yearly thereafter.
Mammography was carried out yearly.
A joint analysis of two randomized trials comparing three with six
cycles of CMF chemotherapy in patients with node-positive breast
cancer revealed similar survival outcomes with markedly less toxicity in
patients receiving three cycles [8]. Therefore, after stratification by
locally determined ER status, patients were randomly assigned to receive
three 28-day courses of ‘classical’ adjuvant CMF chemotherapy
(cyclophosphamide at 100 mg/m2 on days 1–14, orally; methotrexate at
40 mg/m2 on days 1 and 8, intravenously; and 5-fluorouracil at 600 mg/
m2 on days 1 and 8, intravenously) followed by tamoxifen (20 mg/day,
orally for 57 months) (CMF/tamoxifen) or to receive tamoxifen alone
(20 mg/day, orally for 60 months).
statistical methods
The comparisons between treatments were carried out on the intention-to-
treat principle. End points of interest were disease-free survival (DFS),
overall survival (OS), and breast cancer-free interval (BCFI). DFS was
defined as the length of time from the date of randomization to any invasive
breast cancer relapse (including ipsilateral or contralateral breast
recurrence), the appearance of a second nonbreast malignancy, or death,
whichever occurred first. OS was defined as the length of time from the date
of randomization to death from any cause. BCFI was defined as the length
of time from the date of randomization to any invasive breast cancer relapse
(including ipsilateral or contralateral breast recurrence), according to the
‘STEEP (Standardized Definitions for Efficacy End Points) System’ [9] and
was censored at date of last follow-up or at date of death without relapse.
DFS, OS, and BCFI percentages, standard errors, and treatment effect
comparisons were estimated using the Kaplan–Meier method, Greenwood’s
formula, and log-rank tests, respectively. Cox proportional hazards
regression models were used to control for prognostic features, to estimate
hazard ratios (HR) and 95% confidence intervals (CIs) for the treatment
comparisons, and to test for interactions between potential prognostic
factors and treatment effects.
Subpopulation treatment effect pattern plot (STEPP) analysis [10–12]
was used to investigate the pattern of differences in 13-year DFS percentages
Table 1. Patient and tumor characteristics according to estrogen









ER-positive cohort 690 665 1355
Age (years)
<55 116 (17) 122 (18) 238 (18)
55–59 179 (26) 184 (28) 363 (27)
60–64 204 (30) 166 (25) 370 (27)
>65 191 (28) 193 (29) 384 (28)
Surgical treatment
Total mastectomy 323 (47) 332 (50) 655 (48)
Breast conservation 367 (53) 323 (50) 700 (52)
Tumor size (cm)
£1.0 74 (11) 89 (13) 163 (12)
1.1–2.0 341 (49) 325 (49) 666 (49)
>2 254 (37) 227 (34) 481 (36)
Unknown 21 (3) 24 (4) 45 (3)
Tumor grade
1 144 (21) 133 (20) 277 (20)
2 312 (45) 307 (46) 619 (46)
3 196 (28) 182 (27) 378 (28)
Unknown 38 (6) 43 (6) 81 (6)
ER-negative cohort 145 146 291
Age (years)
<55 34 (23) 30 (21) 64 (22)
55–59 27 (19) 37 (25) 64 (22)
60–64 40 (28) 39 (27) 79 (27)
>65 44 (30) 40 (27) 84 (29)
Surgical treatment
Total mastectomy 87 (60) 76 (52) 163 (56)
Breast conservation 58 (40) 70 (48) 128 (44)
Tumor size (cm)
£1.0 15 (10) 9 (6) 24 (8)
1.1–2.0 52 (36) 58 (40) 110 (38)
>2 73 (50) 76 (52) 149 (51)
Unknown 5 (3) 3 (2) 8 (3)
Tumor grade
1 1 (1) 3 (2) 4 (1)
2 40 (28) 27 (18) 67 (23)
3 94 (65) 111 (76) 205 (70)
Unknown 10 (7) 5 (3) 15 (5)
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between treatment arms according to centrally determined quantitative ER
value. Probability values for the interaction test of treatment and ER value
were provided on the basis of simulations.
Cumulative incidence functions were estimated for each of the
competing causes of failure: breast cancer recurrence, second nonbreast
malignancy, and death without prior cancer event. Tests for differences
between treatments were conducted by the method of Gray [13]. All
probability values were obtained from two-sided tests.
ER assays
After the first publication of the trial, ER status was evaluated centrally by
immunohistochemical assay for 1339 patients [14]. Centrally determined
ER status was considered negative, if no ER staining (<1% ) was detected in
the neoplastic cells, and positive for any percentage of ER-positive cells. For
330 patients without central determination of ER status, locally evaluated
ER status was used.
results
The median follow-up time of IBCSG Trial IX is 13.1 years. The
baseline characteristics of the patients are summarized in Table
1. The median age was 60 years (range, 34–81). ERs were
positive in 1355 primary tumors (81%), and 291 patients (17%)
had primary ER-negative tumors. The median number of
axillary lymph nodes examined was 16 (range, 5–47). Eighty-
three percent of patients with breast-conserving surgery had
adjuvant radiation therapy planned at the time of
randomization.
efficacy
Three cycles of CMF chemotherapy did not benefit the patients
with ER-positive breast cancer; 13-year DFS was 64% in
patients with CMF followed by tamoxifen and 66% in patients
treated with tamoxifen only (Figure 1, panel A). In these
patients, OS and BCFI did not differ between the randomized
groups (Figure 1, panels B and C). Similar results were found in
multivariable analysis adjusting for age, tumor size, type of
surgery, and histological grade.
CMF was very efficient in patients with ER-negative
primaries reducing the risk of death or recurrence: 13-year DFS
was 73% in patients treated with CMF followed by
tamoxifen, whereas it was only 57% in patients who were
randomized to receive tamoxifen alone (HR = 0.52; 95% CI
0.35–0.78; P = 0.001; Figure 1, panel D). BCFI was also
improved significantly (13-year BCFI: 80% versus 63%; HR =
0.47; 95% CI 0.30–0.75; P = 0.001; Figure 1, panel F), but the
absolute difference in 13-year OS survival of 10% (79% versus
69%) in favor of chemotherapy was not statistically significant
(HR = 0.69; 95% CI 0.44–1.09; P = 0.11; Figure 1, panel E). This
advantage was maintained after multivariable adjustment for
age, tumor size, type of surgery, and histological grade (data
not shown). The effect of CMF on DFS and BCFI was
statistically significantly different for the two cohorts defined by
ER status (tests for interaction: P = 0.002 for DFS, and P =
0.006 for BCFI); however, the effect on OS was not statistically
significant (test for interaction: P = 0.23 for OS).
The interaction of treatment (CMF followed by tamoxifen
versus tamoxifen alone) with ER expression as centrally
quantified was further investigated in 1339 patients by STEPP
methodology in terms of 13-year DFS percentages (Figure 2).
Two-hundred and sixty-five patients had no ER expression by
central review and they formed the first subpopulation of
STEPP analysis. The subsequent overlapping subpopulations
were formed by dropping the patients with the lowest values for
ER and adding the patients with the next higher values of ER. It
appears that only patients with no or a very low expression of
ER benefit from adjuvant CMF.
long-term toxicity
Acute toxicity was described in detail in a previous report [6]. A
cumulative incidence plot of the three competing causes of
failure (breast cancer recurrence, second nonbreast malignancy,
or death) according to ER status revealed that CMF
chemotherapy had no influence on the incidence of second
nonbreast malignancies or deaths without a cancer event
(Figure 3). The types of second nonbreast malignancies and the
causes of deaths without recurrence for all eligible patients are
summarized in Supplemental Table S1 (available at Annals of
Oncology online). Among patients in the two cohorts, 6.8% on
CMF had a second nonbreast malignancy compared with 6.5%
in the tamoxifen alone group, and deaths without prior cancer
event were 7.2% and 5.9%, respectively.
discussion
Long-term follow-up after a median follow-up period of >13
years confirmed the findings of IBCSG Trial IX originally
reported with 5.9 years of follow-up. Postmenopausal patients
with ER-positive early breast cancer did not benefit from
adjuvant therapy with three courses of oral
cyclophosphamide, methotrexate, and fluorouracil (CMF)
before tamoxifen, but patients with ER-negative breast cancer
experienced substantial benefit; this replicates the observation
reported for pre- and postmenopausal patients with so-called
triple-negative breast cancers [15]. Three and six cycles
yielded similar survival results in a joint analysis of two
randomized controlled trials comparing longer with shorter
chemotherapy [8]. National Surgical Adjuvant Breast and
Bowel Project (NSABP) trial B-20, a randomized controlled
trial comparing tamoxifen with CMF chemotherapy in
combination with and followed by tamoxifen, used six cycles
of CMF and reported no survival benefit of CMF in
postmenopausal patients with node-negative ER-positive
breast cancer [7]. Thus, it is unlikely that a longer
CMF-containing chemotherapy would have generated
a substantially different outcome in this patient population.
The 13-year DFS in patients treated with CMF for ER-negative
tumors was better than in the ER-positive cohort irrespective
of the use of chemotherapy; OS and breast cancer-free interval
were similar in patients with ER-positive tumors and in the
ER-negative cohort treated with CMF.
Aromatase inhibitors are more effective agents than
tamoxifen for prevention of local and distant recurrence [16].
The results of the present trial are therefore certainly applicable
to contemporary adjuvant endocrine therapy incorporating
aromatase inhibitors in postmenopausal patients.
ER expression was centrally determined by
immunohistochemistry for most patients; the comparison
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between the traditional ligand-binding assay and the more
recent immunohistochemistry yielded reasonably high rates of
concordance (88%) between the methods, particularly when
the methods were used to dichotomize the tumors into positive
and negative with respect to ER expression [17]. Thus, the
small number of patients for whom a central determination of
ER status was not possible were assigned the correct ER status
in most cases. Cellular ER content was found to be a predictor
of response to tamoxifen and chemotherapy in NSABP B-20 [7]
with patients whose cancers strongly express ER deriving no
Figure 1. Kaplan–Meier plots for 1355 postmenopausal women with lymph node-negative breast cancer with estrogen receptor-positive [panel A, disease-
free survival (DFS); panel B, overall survival (OS); panel C, breast cancer-free interval (BCFI)] and 291 women with estrogen receptor-negative (panel D,
DFS; panel E, OS; panel F, BCFI) primary tumors at a median follow-up for 13.1 years.
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benefit from CMF chemotherapy. In the current trial, we
observed no such pattern in the patients with ER-positive
tumors [11].
Human epidermal growth factor receptor 2 (HER2) was not
considered in the original trial. However, in a recent report with
central review of HER2 in IBCSG trials VIII and IX Colleoni et al.
observed no clear benefit of CMF in patients with ER-positive
breast cancer [HR (CMF versus no CMF), 0.90, 95% CI 0.74–
1.11] but a significant benefit in the triple-negative group (HR =
0.46, 95% CI 0.29–0.73). The magnitude of CMF efficacy seemed
to be lower in the HER2-positive/endocrine receptor absent group
(HR = 0.58, 95% CI 0.29–1.17) and in the small group of HER2-
positive/endocrine receptor present group (n = 220, HR = 0.73,
95% CI 0.42–1.25) [15]. It is, therefore, unlikely that a separate
analysis by ER and HER2 status could materially influence the
interpretation of this trial.
Highly proliferating breast cancers tend to be more
responsive to chemotherapy than tumors with few cycling cells
[18–20]. Thus, the predictive value of Ki-67, a nuclear antigen
expressed in proliferating cells, was investigated in participants
of IBCSG IX. In contrast to certain other trials [19], centrally
determined Ki-67 labeling index did not predict the efficacy of
CMF chemotherapy relative to tamoxifen alone in the ER-
positive cohort [21].
A multigene marker such as the Oncotype Dx Recurrence
Score is a promising tool to identify patients who benefit from
adjuvant CMF and anthracycline-based chemotherapies [2, 22];
however, the clinical utility of such tests still awaits
confirmation in randomized controlled trials such as TAILORx
[23] and MINDACT [24].
The results of long-term follow-up of IBCSG Trial IX do not
hint toward a chemotherapy-induced overabundance of
nonbreast neoplasias or non-cancer-related deaths. While OS
of the CMF-treated patients was better in the original
publication of Trial IX [6], this was no longer statistically
significant. This observation is likely explained by the later
occurrence of nonbreast cancer causes of death during long-
term follow-up.
In summary, the present report confirms that three courses
of classical CMF chemotherapy have no beneficial effect in
postmenopausal women with lymph node-negative ER-positive
breast cancer treated with adjuvant tamoxifen. In contrast,
CMF is highly efficacious in postmenopausal women with ER-
negative tumors.
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